tazarotene has been researched along with Basal Cell Nevus Syndrome in 1 studies
tazarotene: a topical acetylenic retinoid; a topical kerytolytic
tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.
Basal Cell Nevus Syndrome: Hereditary disorder consisting of multiple basal cell carcinomas, odontogenic keratocysts, and multiple skeletal defects, e.g., frontal and temporoparietal bossing, bifurcated and splayed ribs, kyphoscoliosis, fusion of vertebrae, and cervicothoracic spina bifida. Genetic transmission is autosomal dominant.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tang, JY | 1 |
| Chiou, AS | 1 |
| Mackay-Wiggan, JM | 1 |
| Aszterbaum, M | 1 |
| Chanana, AM | 1 |
| Lee, W | 1 |
| Lindgren, JA | 1 |
| Raphael, MA | 1 |
| Thompson, BJ | 1 |
| Bickers, DR | 1 |
| Epstein, EH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Single Arm Open-Label Clinical Trial of Chemotherapy of BCC's With Tazarotene 0.1% in Subjects With Basal Cell Nevus Syndrome[NCT00489086] | Phase 2 | 36 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary endpoint used to evaluate tazarotene efficacy for BCC chemotherapy was the complete response (CR) rate, defined as the complete visible disappearance of a patient's target lesion during the the 18 months of tazarotene application and its failure to recur during the ensuing 18-months. We defined surgical removal of a target lesion as a treatment failure. The primary endpoint was assessed based on intention to treat analysis such that any subject who underwent the baseline evaluation and applied at least 1 dose of tazarotene was included in the analysis. Drop-outs were considered non-responders. A priori treatment success for tazarotene was defined as a CR rate of at least 50%, and treatment failure was defined as a CR rate of 25% or less." (NCT00489086)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Tazarotene Cream | 2 |
(NCT00489086)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Tazarotene Cream | NA |
(NCT00489086)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Tazarotene Cream | NA |
(NCT00489086)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Tazarotene Cream | NA |
(NCT00489086)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Tazarotene Cream | NA |
1 trial available for tazarotene and Basal Cell Nevus Syndrome
| Article | Year |
|---|---|
Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndrome.
Topics: Adult; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Cross-Over Studies; Dermatologic Agents; Do | 2014 |